Intelligence Β· Clinical Pipeline

PTC THERAPEUTICS Pipeline

All ClinicalTrials.gov programs at PTC THERAPEUTICS β€” phase, modality, and trial IDs.

Programs
23

Quick answer

PTC THERAPEUTICS has 23 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. AAV2-hAADC

    PTC THERAPEUTICS, INC.

    Aromatic Amino Acid Decarboxylase Deficiency

    phase 2 small molecule completed

    1 trial
  2. Ataluren

    PTC THERAPEUTICS, INC.

    Amino Acid Metabolism, Inborn Errors

    phase 2 small molecule terminated

    1 trial
  3. Ataluren

    PTC THERAPEUTICS, INC.

    Aniridia

    phase 2 small molecule terminated

    2 trials
  4. Ataluren

    PTC THERAPEUTICS, INC.

    Hemophilia A

    phase 2 small molecule terminated

    1 trial
  5. Ataluren

    PTC THERAPEUTICS, INC.

    Nonsene Mutation Duchenne Muscular Dystrophy

    phase 2 small molecule completed

    1 trial
  6. Ataluren + Pembrolizumab

    PTC THERAPEUTICS, INC.

    Colorectal Cancer

    phase 2 small molecule active

    1 trial
  7. CNSA-001

    PTC THERAPEUTICS, INC.

    Gastroparesis

    phase 2 small molecule completed

    1 trial
  8. EPI-589

    PTC THERAPEUTICS, INC.

    Amyotrophic Lateral Sclerosis

    phase 2 small molecule completed

    1 trial
  9. EPI-743

    PTC THERAPEUTICS, INC.

    Leigh Syndrome

    phase 2 small molecule completed

    1 trial
  10. Eladocagene Exuparvovec

    PTC THERAPEUTICS, INC.

    AADC Deficiency

    phase 2 gene therapy active

    1 trial
  11. PTC124

    PTC THERAPEUTICS, INC.

    Duchenne Muscular Dystrophy

    phase 2 small molecule completed

    1 trial
  12. PTC124

    PTC THERAPEUTICS, INC.

    Cystic Fibrosis

    phase 2 small molecule completed

    2 trials
  13. PTC299

    PTC THERAPEUTICS, INC.

    Neurofibromatosis 2

    phase 2 small molecule terminated

    1 trial
  14. PTC518

    PTC THERAPEUTICS, INC.

    Huntington Disease

    phase 2 small molecule completed

    1 trial
  15. PTC857

    PTC THERAPEUTICS, INC.

    Amyotrophic Lateral Sclerosis

    phase 2 small molecule terminated

    1 trial
  16. PTC857, Placebo to match PTC857 60 mg/mL oral solution, Utreloxastat 62.5

    PTC THERAPEUTICS, INC.

    Amyotrophic Lateral Sclerosis

    phase 2 small molecule active

    1 trial
  17. PTC923

    PTC THERAPEUTICS, INC.

    BH4 Deficiency

    phase 2 small molecule completed

    1 trial
  18. Placebo

    PTC THERAPEUTICS, INC.

    Friedreich's Ataxia

    phase 2 small molecule completed

    1 trial
  19. Placebo

    PTC THERAPEUTICS, INC.

    Leigh Syndrome

    phase 2 small molecule completed

    1 trial
  20. Placebo to match 5-mg PTC518 tablets, Placebo to match 20-mg PTC518 tablets, PTC518, PTC518

    PTC THERAPEUTICS, INC.

    Huntington’s Disease

    phase 2 small molecule active

    1 trial
  21. VEGF inhibitor PTC299

    PTC THERAPEUTICS, INC.

    Kaposi's Sarcoma

    phase 2 small molecule terminated

    1 trial
  22. ataluren

    PTC THERAPEUTICS, INC.

    Epilepsy

    phase 2 small molecule completed

    1 trial
  23. gene therapy

    PTC THERAPEUTICS, INC.

    Aromatic L-amino Acid Decarboxylase (AADC) Deficiency

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many pipeline programs does PTC THERAPEUTICS have?

23 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources Β· All pipeline programs